GUFICBIO — Gufic Biosciences Balance Sheet
0.000.00%
- IN₹39.29bn
- IN₹42.58bn
- IN₹9.44bn
Annual balance sheet for Gufic Biosciences, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
C2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | 2026 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IAS | IAS | IAS | IAS | IAS |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 265 | 467 | 135 | 290 | 762 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 1,778 | 2,322 | 3,828 | 3,771 | 3,994 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 3,208 | 4,641 | 6,005 | 6,245 | 8,021 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 1,554 | 3,285 | 4,603 | 5,215 | 5,070 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 5,214 | 8,612 | 10,925 | 11,694 | 13,424 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 1,864 | 2,882 | 3,720 | 3,876 | 5,178 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Funded Status | |||||
| Total Liabilities | 2,523 | 5,134 | 5,600 | 5,683 | 6,774 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Total Equity | 2,691 | 3,478 | 5,326 | 6,011 | 6,649 |
| Total Liabilities & Shareholders' Equity | 5,214 | 8,612 | 10,925 | 11,694 | 13,424 |
| Total Common Shares Outstanding |